International Society of Urological Pathology (ISUP) Consensus Conference on Current Issues in Bladder Cancer. Working Group 2: Grading of Mixed Grade, Invasive Urothelial Carcinoma Including Histologic Subtypes and Divergent Differentiations, and Non-Urothelial Carcinomas.
Journal
The American journal of surgical pathology
ISSN: 1532-0979
Titre abrégé: Am J Surg Pathol
Pays: United States
ID NLM: 7707904
Informations de publication
Date de publication:
29 Jun 2023
29 Jun 2023
Historique:
medline:
29
6
2023
pubmed:
29
6
2023
entrez:
29
6
2023
Statut:
aheadofprint
Résumé
The 2022 International Society of Urological Pathology (ISUP) Consensus Conference on Urinary Bladder Cancer Working Group 2 was tasked to provide evidence-based proposals on the applications of grading in noninvasive urothelial carcinoma with mixed grades, invasive urothelial carcinoma including subtypes (variants) and divergent differentiations, and in pure non-urothelial carcinomas. Studies suggested that predominantly low-grade noninvasive papillary urothelial carcinoma with focal high-grade component has intermediate outcome between low- and high-grade tumors. However, no consensus was reached on how to define a focal high-grade component. By 2004 WHO grading, the vast majority of lamina propria-invasive (T1) urothelial carcinomas are high-grade, and the rare invasive low-grade tumors show only limited superficial invasion. While by 1973 WHO grading, the vast majority of T1 urothelial carcinomas are G2 and G3 and show significant differences in outcome based on tumor grade. No consensus was reached if T1 tumors should be graded either by the 2004 WHO system or by the 1973 WHO system. Because of the concern for underdiagnosis and underreporting with potential undertreatment, participants unanimously recommended that the presence of urothelial carcinoma subtypes and divergent differentiations should be reported. There was consensus that the extent of these subtypes and divergent differentiations should also be documented in biopsy, transurethral resection, and cystectomy specimens. Any distinct subtype and divergent differentiation should be diagnosed without a threshold cutoff, and each type should be enumerated in tumors with combined morphologies. The participants agreed that all subtypes and divergent differentiations should be considered high-grade according to the 2004 WHO grading system. However, participants strongly acknowledged that subtypes and divergent differentiations should not be considered as a homogenous group in terms of behavior. Thus, future studies should focus on individual subtypes and divergent differentiations rather than lumping these different entities into a single clinicopathological group. Likewise, clinical recommendations should pay attention to the potential heterogeneity of subtypes and divergent differentiations in terms of behavior and response to therapy. There was consensus that invasive pure squamous cell carcinoma and pure adenocarcinoma of the bladder should be graded according to the degree of differentiation. In conclusion, this summary of the International Society of Urological Pathology Working Group 2 proceedings addresses some of the issues on grading beyond its traditional application, including for papillary urothelial carcinomas with mixed grades and with invasive components. Reporting of subtypes and divergent differentiation is also addressed in detail, acknowledging their role in risk stratification. This report could serve as a guide for best practices and may advise future research and proposals on the prognostication of these tumors.
Identifiants
pubmed: 37382156
doi: 10.1097/PAS.0000000000002077
pii: 00000478-990000000-00199
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Investigateurs
Adebowale Adeniran
(A)
Hikmat Al-Ahimadie
(H)
Fernando Algaba
(F)
Yves Allory Selina Bhattarai
(YAS)
Peter Black
(P)
David Berman
(D)
Simone Bertz
(S)
Lukas Bubendorf
(L)
Birgitte Carlsen
(B)
Rita Carvalho
(R)
Liang Cheng
(L)
Obinna Chijioke
(O)
Yong Mee Cho
(YM)
Eva Comperat
(E)
Isabela di Cunha
(I)
Julien Dagher
(J)
Isabella de Cunha
(I)
Brett Delahunt
(B)
Michelle Downes
(M)
Thomas Flaig
(T)
Achim Fleischmann
(A)
Cosmin Florescu
(C)
Jacqueline Fontugne
(J)
Vera Genitsch
(V)
Guro Horni Gløersen
(GH)
Michael von Gunten
(M)
Rainer Grobholz
(R)
Donna Hansel
(D)
Arndt Hartmann
(A)
Loren Herrera Hernandez
(LH)
Mattias Hogland
(M)
Jiaoti Huang
(J)
Brad Jensen
(B)
Kenneth Iczkowski
(K)
Rafael Jimenez
(R)
Bojana Jovanovic
(B)
Ashish Kamat
(A)
Jens Koellermann
(J)
Trevor Levin
(T)
Fredrik Liedberg
(F)
Antonio Lopez-Beltran
(A)
Anand C Loya
(AC)
Marianne Lyngra
(M)
Teresa McHale
(T)
Khadidja Mokeddem
(K)
George Netto
(G)
Maya Nourieh
(M)
Declan O'Rourke
(D)
Irina-Alexandra Ostahi
(IA)
Gladell Paner
(G)
Maria M Picken
(MM)
Flavia Guzman Pineda
(FG)
Camelia Radulescu Maria Raspollini
(CRM)
Henning Reis
(H)
Shi Ruoyu
(S)
Hemamali Samaratunga
(H)
Remi Semba
(R)
Nigam Shah
(N)
Steven Shen
(S)
Steven Smith
(S)
Tovia Smith
(T)
John Srigley
(J)
Sueli Suzigan
(S)
Nicole Swarbrick
(N)
Ildiko Szalay
(I)
Inger Talleraas
(I)
Jean-Christophe Tille
(JC)
Marieta Toma
(M)
Isabel Trias
(I)
Toyonori Tsuzuki
(T)
Theodorus van der Kwast
(T)
Bas van Rhijn
(B)
Murali Varma
(M)
Sofie Verbeke
(S)
Sangeeta Verma
(S)
Tatjana Vlajnic
(T)
Ljiljana Vlatkovic
(L)
Anne Warren
(A)
Joshua Warrick
(J)
Sean Williamson
(S)
Sara Wobker
(S)
Clifton Woods
(C)
Chen Yang
(C)
Ghilsuk Yoon
(G)
Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest and Source of Funding: The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.
Références
Mostofi FK, Sobin LH, Torloni H. International Histological Classification of Tumours Histological Typing of Urinary Bladder Tumours. Geneva, Switzerland: World Health Organization; 1973.
Epstein JI, Amin MB, Reuter VR, et al. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol. 1998;22:1435–1448.
Eble JN, Sauter G, Epstein JI, Sesterhenn IA. World Health Organization Classification of Tumours Pathology & Genetics Tumours of the Urinary System and Male Genital Organs. Geneva, Switzerland: World Health Organization; 2004.
Moch H, Humphrey PA, Ulbright TM, Reuter VE. WHO Classification of Tumours of the Urinary System and Male Genital Organs. Geneva, Switzerland: WHO Press; 2016.
WHO. Classification of Tumours Editorial Board. WHO Classification of Tumours 5th Edition Urinary and Male Genital Tumours. Lyon: International Agency for Research on Cancer; 2022.
Lopez-Beltran A, Henriques V, Montironi R, et al. Variants and new entities of bladder cancer. Histopathology. 2019;74:77–96.
Veskimae E, Espinos EL, Bruins HM, et al. What is the prognostic and clinical importance of urothelial and nonurothelial histological variants of bladder cancer in predicting oncological outcomes in patients with muscle-invasive and metastatic bladder cancer? A European Association of Urology muscle invasive and metastatic bladder cancer guidelines panel systematic review. Eur Urol Oncol. 2019;2:625–642.
Lobo N, Shariat SF, Guo CC, et al. What is the significance of variant histology in urothelial carcinoma? Eur Urol Focus. 2020;6:653–663.
Amin MB, Smith SC, Reuter VE, et al. Update for the practicing pathologist: The International Consultation On Urologic Disease-European Association of Urology consultation on bladder cancer. Mod Pathol. 2015;28:612–630.
Babjuk M, Burger M, Capoun O, et al. European Association of Urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ). Eur Urol. 2022;81:75–94.
Chang SS, Boorjian SA, Chou R, et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline. J Urol. 2016;196:1021–1029.
Bladder cancer. diagnosis and management of bladder cancer: (c) NICE (2015) Bladder cancer: diagnosis and management of bladder cancer. BJU Int. 2017;120:755–765.
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Bladder Cancer. Version 3.2022.Accessed December 23, 2022. http://nccn.org
Cheng L, Neumann RM, Nehra A, et al. Cancer heterogeneity and its biologic implications in the grading of urothelial carcinoma. Cancer. 2000;88:1663–1670.
Schubert T, Danzig MR, Kotamarti S, et al. Mixed low- and high-grade non-muscle-invasive bladder cancer: a histological subtype with favorable outcome. World J Urol. 2015;33:847–852.
Gofrit ON, Pizov G, Shapiro A, et al. Mixed high and low grade bladder tumors--are they clinically high or low grade? J Urol. 2014;191:1693–1696.
Ho P, Moran GW, Wang V, et al. The effect of tumor grade heterogeneity on recurrence in non-muscle invasive bladder cancer. Urol Oncol. 2022;40:60.e11–60.e16.
Reis LO, Taheri D, Chaux A, et al. Significance of a minor high-grade component in a low-grade noninvasive papillary urothelial carcinoma of bladder. Hum Pathol. 2016;47:20–25.
Culpan M, Keser F, Iplikci A, et al. The clinical impact of tumor grade heterogeneity in non-muscle-invasive urothelial carcinoma of the bladder. Medeni Med J. 2021;36:310–317.
Downes MR, Weening B, van Rhijn BW, et al. Analysis of papillary urothelial carcinomas of the bladder with grade heterogeneity: supportive evidence for an early role of CDKN2A deletions in the FGFR3 pathway. Histopathology. 2017;70:281–289.
Billis A, Carvalho RB, Mattos AC, et al. Tumor grade heterogeneity in urothelial bladder carcinoma--proposal of a system using combined numbers. Scand J Urol Nephrol. 2001;35:275–279.
Cao D, Vollmer RT, Luly J, et al. Comparison of 2004 and 1973 World Health Organization grading systems and their relationship to pathologic staging for predicting long-term prognosis in patients with urothelial carcinoma. Urology. 2010;76:593–599.
Otto W, Denzinger S, Fritsche HM, et al. The WHO classification of 1973 is more suitable than the WHO classification of 2004 for predicting survival in pT1 urothelial bladder cancer. BJU Int. 2011;107:404–408.
Pellucchi F, Freschi M, Moschini M, et al. Oncological predictive value of the 2004 World Health Organisation grading classification in primary T1 non-muscle-invasive bladder cancer. A step forward or back? BJU Int. 2015;115:267–273.
van de Putte EEF, Bosschieter J, van der Kwast TH, et al. The World Health Organization 1973 classification system for grade is an important prognosticator in T1 non-muscle-invasive bladder cancer. BJU Int, 2018:978–985.
Toll AD, Epstein JI. Invasive low-grade papillary urothelial carcinoma: a clinicopathologic analysis of 41 cases. Am J Surg Pathol. 2012;36:1081–1086.
Watts KE, Montironi R, Mazzucchelli R, et al. Clinicopathologic characteristics of 23 cases of invasive low-grade papillary urothelial carcinoma. Urology. 2012;80:361–366.
Pan CC, Chang YH, Chen KK, et al. Prognostic significance of the 2004 WHO/ISUP classification for prediction of recurrence, progression, and cancer-specific mortality of non-muscle-invasive urothelial tumors of the urinary bladder: a clinicopathologic study of 1,515 cases. Am J Clin Pathol. 2010;133:788–795.
Mikulowski P, Hellsten S. T1 G1 urinary bladder carcinoma: fact or fiction? Scand J Urol Nephrol. 2005;39:135–137.
van Rhijn BW, van der Kwast TH, Kakiashvili DM, et al. Pathological stage review is indicated in primary pT1 bladder cancer. BJU Int. 2010;106:206–211.
Downes MR, Lajkosz K, Kuk C, et al. The impact of grading scheme on non-muscle invasive bladder cancer progression: potential utility of hybrid grading schemes. Pathology. 2022;54:425–433.
Beijert IJ, Hentschel AE, Brundl J, et al. T1G1 bladder cancer: prognosis for this rare pathological diagnosis within the non-muscle-invasive bladder cancer spectrum. Eur Urol Focus. 2022;8:1627–1634.
Kamel MH, Daly PJ, Khan MF, et al. Survival and progression in high grade tumour subset of G2 and G3 pT1 bladder transitional cell carcinoma. Eur J Surg Oncol. 2006;32:1139–1143.
Varma M, Delahunt B, van der Kwast T. Grading noninvasive bladder cancer: World Health Organisation 1973 or 2004 may be the wrong question. Eur Urol. 2019;76:413–415.
Shah RB, Montgomery JS, Montie JE, et al. Variant (divergent) histologic differentiation in urothelial carcinoma is under-recognized in community practice: impact of mandatory central pathology review at a large referral hospital. Urol Oncol. 2013;31:1650–1655.
Linder BJ, Boorjian SA, Cheville JC, et al. The impact of histological reclassification during pathology re-review--evidence of a Will Rogers effect in bladder cancer? J Urol. 2013;190:1692–1696.
Cimadamore A, Lonati C, Di Trapani E, et al. Variant histologies in bladder cancer: Does the centre have an impact in detection accuracy? Urol Oncol. 2022;40:273.e11–273.e20.
Lonati C, Baumeister P, Ornaghi PI, et al. Accuracy of transurethral resection of the bladder in detecting variant histology of bladder cancer compared with radical cystectomy. Eur Urol Focus. 2022;8:457–464.
Abd El-Latif A, Watts KE, Elson P, et al. The sensitivity of initial transurethral resection or biopsy of bladder tumor(s) for detecting bladder cancer variants on radical cystectomy. J Urol. 2013;189:1263–1267.
Paner GP, Montironi R. Re: J. Alfred Witjes, Harman Max Bruins, Richard Cathomas, et al. European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines. Eur Urol 2021;79:82-104: Importance of standardized pathology reporting for urological cancers in the implementation of urology guidelines. Eur Urol. 2021;79:e30–e32.
Sangoi AR, Beck AH, Amin MB, et al. Interobserver reproducibility in the diagnosis of invasive micropapillary carcinoma of the urinary tract among urologic pathologists. Am J Surg Pathol. 2010;34:1367–1376.
Wasco MJ, Daignault S, Bradley D, et al. Nested variant of urothelial carcinoma: a clinicopathologic and immunohistochemical study of 30 pure and mixed cases. Hum Pathol. 2010;41:163–171.
Beltran AL, Cheng L, Montironi R, et al. Clinicopathological characteristics and outcome of nested carcinoma of the urinary bladder. Virchows Arch. 2014;465:199–205.
Lopez Beltran A, Montironi R, Cheng L. Microcystic urothelial carcinoma: morphology, immunohistochemistry and clinical behaviour. Histopathology. 2014;64:872–879.
Sanfrancesco J, McKenney JK, Leivo MZ, et al. Sarcomatoid urothelial carcinoma of the bladder: analysis of 28 cases with emphasis on clinicopathologic features and markers of epithelial-to-mesenchymal transition. Arch Pathol Lab Med. 2016;140:543–551.
Amin MB, Ro JY, el-Sharkawy T, et al. Micropapillary variant of transitional cell carcinoma of the urinary bladder. Histologic pattern resembling ovarian papillary serous carcinoma. Am J Surg Pathol. 1994;18:1224–1232.
Samaratunga H, Khoo K. Micropapillary variant of urothelial carcinoma of the urinary bladder; a clinicopathological and immunohistochemical study. Histopathology. 2004;45:55–64.
Comperat E, Roupret M, Yaxley J, et al. Micropapillary urothelial carcinoma of the urinary bladder: a clinicopathological analysis of 72 cases. Pathology. 2010;42:650–654.
Diamantopoulos LN, Holt SK, Khaki AR, et al. Response to neoadjuvant chemotherapy and survival in micropapillary urothelial carcinoma: data from a tertiary referral center and the Surveillance, Epidemiology, and End Results (SEER) program. Clin Genitourin Cancer. 2021;19:144–154.
Ro JY, Shen SS, Lee HI, et al. Plasmacytoid transitional cell carcinoma of urinary bladder: a clinicopathologic study of 9 cases. Am J Surg Pathol. 2008;32:752–757.
Nigwekar P, Tamboli P, Amin MB, et al. Plasmacytoid urothelial carcinoma: detailed analysis of morphology with clinicopathologic correlation in 17 cases. Am J Surg Pathol. 2009;33:417–424.
Lopez-Beltran A, Requena MJ, Montironi R, et al. Plasmacytoid urothelial carcinoma of the bladder. Hum Pathol. 2009;40:1023–1028.
Dayyani F, Czerniak BA, Sircar K, et al. Plasmacytoid urothelial carcinoma, a chemosensitive cancer with poor prognosis, and peritoneal carcinomatosis. J Urol. 2013;189:1656–1661.
Perrino CM, Eble J, Kao CS, et al. Plasmacytoid/diffuse urothelial carcinoma: a single-institution immunohistochemical and molecular study of 69 patients. Hum Pathol. 2019;90:27–36.
Comperat E, McKenney JK, Hartmann A, et al. Large nested variant of urothelial carcinoma: a clinicopathological study of 36 cases. Histopathology. 2017;71:703–710.
Williamson SR, Zhang S, Lopez-Beltran A, et al. Lymphoepithelioma-like carcinoma of the urinary bladder: clinicopathologic, immunohistochemical, and molecular features. Am J Surg Pathol. 2011;35:474–483.
Leroy X, Gonzalez S, Zini L, et al. Lipoid-cell variant of urothelial carcinoma: a clinicopathologic and immunohistochemical study of five cases. Am J Surg Pathol. 2007;31:770–773.
Lopez-Beltran A, Amin MB, Oliveira PS, et al. Urothelial carcinoma of the bladder, lipid cell variant: clinicopathologic findings and LOH analysis. Am J Surg Pathol. 2010;34:371–376.
Behzatoglu K. Urothelial carcinoma with shadow cell, lipid cell and sebaceous (skin adnexal) differentiation: clinicopathological and immunohistochemical study of 10 cases. Ann Diagn Pathol. 2015;19:314–319.
Lopez-Beltran A, Blanca A, Montironi R, et al. Pleomorphic giant cell carcinoma of the urinary bladder. Hum Pathol. 2009;40:1461–1466.
Samaratunga H, Delahunt B, Egevad L, et al. Pleomorphic giant cell carcinoma of the urinary bladder: an extreme form of tumour de-differentiation. Histopathology. 2016;68:533–540.
Przybycin CG, McKenney JK, Nguyen JK, et al. Urothelial carcinomas with trophoblastic differentiation, including choriocarcinoma: clinicopathologic series of 16 cases. Am J Surg Pathol. 2020;44:1322–1330.
Kim SP, Frank I, Cheville JC, et al. The impact of squamous and glandular differentiation on survival after radical cystectomy for urothelial carcinoma. J Urol. 2012;188:405–409.
Linder BJ, Frank I, Cheville JC, et al. Outcomes following radical cystectomy for nested variant of urothelial carcinoma: a matched cohort analysis. J Urol. 2013;189:1670–1675.
Izard JP, Siemens DR, Mackillop WJ, et al. Outcomes of squamous histology in bladder cancer: a population-based study. Urol Oncol. 2015;33:425:e7–e13.
Laymon M, Mosbah A, Hashem A, et al. Oncologic outcomes of squamous cell carcinoma versus urothelial carcinoma with squamous differentiation after radical cystectomy for bladder carcinoma. Clin Genitourin Cancer. 2022;20:148–154.
Wright JL, Black PC, Brown GA, et al. Differences in survival among patients with sarcomatoid carcinoma, carcinosarcoma and urothelial carcinoma of the bladder. J Urol. 2007;178:2302–2306.
Wang J, Wang FW, Lagrange CA, et al. Clinical features of sarcomatoid carcinoma (carcinosarcoma) of the urinary bladder: analysis of 221 cases. Sarcoma. 2010;2010:454792.
Almassi N, Vertosick EA, Sjoberg DD, et al. Pathological and oncological outcomes in patients with sarcomatoid differentiation undergoing cystectomy. BJU Int. 2022;129:463–469.
Diamantopoulos LN, Korentzelos D, Alevizakos M, et al. Sarcomatoid urothelial carcinoma: a population-based study of clinicopathologic characteristics and survival outcomes. Clin Genitourin Cancer. 2022;20:139–147.
Kamat AM, Dinney CP, Gee JR, et al. Micropapillary bladder cancer: a review of the University of Texas M. D. Anderson Cancer Center experience with 100 consecutive patients. Cancer. 2007;110:62–67.
Wang JK, Boorjian SA, Cheville JC, et al. Outcomes following radical cystectomy for micropapillary bladder cancer versus pure urothelial carcinoma: a matched cohort analysis. World J Urol. 2012;30:801–806.
Fairey AS, Daneshmand S, Wang L, et al. Impact of micropapillary urothelial carcinoma variant histology on survival after radical cystectomy. Urol Oncol. 2014;32:110–116.
Sui W, Matulay JT, James MB, et al. Micropapillary bladder cancer: insights from the National Cancer Database. Bladder Cancer. 2016;2:415–423.
Abufaraj M, Foerster B, Schernhammer E, et al. Micropapillary urothelial carcinoma of the bladder: a systematic review and meta-analysis of disease characteristics and treatment outcomes. Eur Urol. 2019;75:649–658.
Mitra AP, Fairey AS, Skinner EC, et al. Implications of micropapillary urothelial carcinoma variant on prognosis following radical cystectomy: A multi-institutional investigation. Urol Oncol. 2019;37:48–56.
Jin D, Jin K, Qiu S, et al. Prognostic values of the clinicopathological characteristics and survival outcomes in micropapillary urothelial carcinoma of the bladder: A SEER database analysis. Cancer Med. 2020;9:4897–4906.
Kaimakliotis HZ, Monn MF, Cary KC, et al. Plasmacytoid variant urothelial bladder cancer: is it time to update the treatment paradigm? Urol Oncol. 2014;32:833–838.
Cockerill PA, Cheville JC, Boorjian SA, et al. Outcomes following radical cystectomy for plasmacytoid urothelial carcinoma: defining the need for improved local cancer control. Urology. 2017;102:143–147.
Li Q, Assel M, Benfante NE, et al. The impact of plasmacytoid variant histology on the survival of patients with urothelial carcinoma of bladder after radical cystectomy. Eur Urol Focus. 2019;5:104–108.
Vetterlein MW, Wankowicz SAM, Seisen T, et al. Neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer with variant histology. Cancer. 2017;123:4346–4355.
Mitra AP, Bartsch CC, Bartsch G Jr, et al. Does presence of squamous and glandular differentiation in urothelial carcinoma of the bladder at cystectomy portend poor prognosis? An intensive case-control analysis. Urol Oncol. 2014;32:117–127.
Cox R, Epstein JI. Large nested variant of urothelial carcinoma: 23 cases mimicking von Brunn nests and inverted growth pattern of noninvasive papillary urothelial carcinoma. Am J Surg Pathol. 2011;35:1337–1342.
Mai KT, Bateman J, Djordjevic B, et al. Clear cell urothelial carcinoma. Int J Surg Pathol. 2017;25:18–25.
Baydar D, Amin MB, Epstein JI. Osteoclast-rich undifferentiated carcinomas of the urinary tract. Mod Pathol. 2006;19:161–171.
Soave A, Schmidt S, Dahlem R, et al. Does the extent of variant histology affect oncological outcomes in patients with urothelial carcinoma of the bladder treated with radical cystectomy? Urol Oncol. 2015;33:21.e1–21.e9.
Ehdaie B, Maschino A, Shariat SF, et al. Comparative outcomes of pure squamous cell carcinoma and urothelial carcinoma with squamous differentiation in patients treated with radical cystectomy. J Urol. 2012;187:74–79.
Monn MF, Kaimakliotis HZ, Pedrosa JA, et al. Contemporary bladder cancer: variant histology may be a significant driver of disease. Urol Oncol. 2015;33:18.e15–20.
Xylinas E, Rink M, Robinson BD, et al. Impact of histological variants on oncological outcomes of patients with urothelial carcinoma of the bladder treated with radical cystectomy. Eur J Cancer. 2013;49:1889–1897.
Moschini M, Dell’Oglio P, Luciano R, et al. Incidence and effect of variant histology on oncological outcomes in patients with bladder cancer treated with radical cystectomy. Urol Oncol. 2017;35:335–341.
Patel SG, Weiner AB, Keegan K, et al. Oncologic outcomes in patients with nonurothelial bladder cancer. Indian J Urol. 2018;34:39–44.
Bertz S, Wach S, Taubert H, et al. Micropapillary morphology is an indicator of poor prognosis in patients with urothelial carcinoma treated with transurethral resection and radiochemotherapy. Virchows Arch. 2016;469:339–344.
Keck B, Wach S, Stoehr R, et al. Plasmacytoid variant of bladder cancer defines patients with poor prognosis if treated with cystectomy and adjuvant cisplatin-based chemotherapy. BMC Cancer. 2013;13:71.
Fernandez MI, Williams SB, Willis DL, et al. Clinical risk stratification in patients with surgically resectable micropapillary bladder cancer. BJU Int. 2017;119:684–691.
Royce TJ, Lin CC, Gray PJ, et al. Clinical characteristics and outcomes of nonurothelial cell carcinoma of the bladder: Results from the National Cancer Data Base. Urol Oncol. 2018;36:78.e1–78.e12.
Jue JS, Koru-Sengul T, Moore KJ, et al. Sociodemographic and survival disparities for histologic variants of bladder cancer. Can J Urol. 2018;25:9179–9185.
Mally AD, Tin AL, Lee JK, et al. Clinical outcomes of patients with T1 nested variant of urothelial carcinoma compared to pure urothelial carcinoma of the bladder. Clin Genitourin Cancer. 2017;S1558-7673:30199–4.
Tamas EF, Nielsen ME, Schoenberg MP, et al. Lymphoepithelioma-like carcinoma of the urinary tract: a clinicopathological study of 30 pure and mixed cases. Mod Pathol. 2007;20:828–834.
Necchi A, Raggi D, Gallina A, et al. Updated results of PURE-01 with preliminary activity of neoadjuvant pembrolizumab in patients with muscle-invasive bladder carcinoma with variant histologies. Eur Urol. 2020;77:439–446.
Willis DL, Fernandez MI, Dickstein RJ, et al. Clinical outcomes of cT1 micropapillary bladder cancer. J Urol. 2015;193:1129–1134.
Witjes JA, Babjuk M, Bellmunt J, et al. EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multistakeholder effort: under the auspices of the EAU-ESMO guidelines committees. Eur Urol. 2020;77:223–250.
Kaimakliotis HZ, Monn MF, Cheng L, et al. Plasmacytoid bladder cancer: variant histology with aggressive behavior and a new mode of invasion along fascial planes. Urology. 2014;83:1112–1116.
Lopez-Beltran A, Blanca A, Cimadamore A, et al. T1 bladder carcinoma with variant histology: pathological features and clinical significance. Virchows Arch. 2022;480:989–998.
Hajiran A, Azizi M, Aydin AM, et al. Pathological and survival outcomes associated with variant histology bladder cancers managed by cystectomy with or without neoadjuvant chemotherapy. J Urol. 2021;205:100–108.
Chakiryan NH, Jiang DD, Gillis KA, et al. Pathological downstaging and survival outcomes associated with neoadjuvant chemotherapy for variant histology muscle invasive bladder cancer. J Urol. 2021;206:924–932.
Lopez-Beltran A, Cheng L, Prieto R, et al. Lymphoepithelioma-like carcinoma of the prostate. Hum Pathol. 2009;40:982–987.
Amin MB, Ro JY, Lee KM, et al. Lymphoepithelioma-like carcinoma of the urinary bladder. Am J Surg Pathol. 1994;18:466–473.
Yang AW, Pooli A, Lele SM, et al. Lymphoepithelioma-like, a variant of urothelial carcinoma of the urinary bladder: a case report and systematic review for optimal treatment modality for disease-free survival. BMC Urol. 2017;17:34.
Cox RM, Schneider AG, Sangoi AR, et al. Invasive urothelial carcinoma with chordoid features: a report of 12 distinct cases characterized by prominent myxoid stroma and cordlike epithelial architecture. Am J Surg Pathol. 2009;33:1213–1219.
Paner GP, Cox RM, Richards K, et al. Pseudoangiosarcomatous urothelial carcinoma of the urinary bladder. Am J Surg Pathol. 2014;38:1251–1259.
Hansel DE, Amin MB, Comperat E, et al. A contemporary update on pathology standards for bladder cancer: transurethral resection and radical cystectomy specimens. Eur Urol. 2013;63:321–332.
Paner GP, Zhou M, Srigley JR, et al. College of American Pathologists. Protocols for the examination of cystectomy specimens from patients with carcinoma of the urinary bladder. June 2021. Accessed April 1, 2023. https://www.cap.org/protocols-and-guidelines.
Lagwinski N, Thomas A, Stephenson AJ, et al. Squamous cell carcinoma of the bladder: a clinicopathologic analysis of 45 cases. Am J Surg Pathol. 2007;31:1777–1787.
El-Sebaie M, Zaghloul MS, Howard G, et al. Squamous cell carcinoma of the bilharzial and non-bilharzial urinary bladder: a review of etiological features, natural history, and management. Int J Clin Oncol. 2005;10:20–25.
Zhang G, Li Z, Song D, et al. Nomograms to predict individual prognosis of patients with squamous cell carcinoma of the urinary bladder. BMC Cancer. 2019;19:1200.
Anderstrom C, Johansson SL, von Schultz L. Primary adenocarcinoma of the urinary bladder. A clinicopathologic and prognostic study. Cancer. 1983;52:1273–1280.
Zaghloul MS, Nouh A, Nazmy M, et al. Long-term results of primary adenocarcinoma of the urinary bladder: a report on 192 patients. Urol Oncol. 2006;24:13–20.
Zaffuto E, Gazdovich S, Leyh-Bannurah SR, et al. Contemporary rates of pathological features and mortality for adenocarcinoma of the urinary bladder in the USA. Int J Urol. 2017;24:117–123.
Natale C, Leinwand GZ, Chiang J, et al. Reviewing the demographic, prognostic, and treatment factors of primary adenocarcinoma of the bladder: a SEER population-based study. Clin Genitourin Cancer. 2019;17:380–388.
Yu DD, Dong H, Chen WK, et al. Development and validation of a nomogram for predicting survival in patients with non-metastatic primary adenocarcinoma of the bladder. Transl Cancer Res. 2020;9:5155–5165.
Lu H, Zhu W, Mao W, et al. Trends of incidence and prognosis of primary adenocarcinoma of the bladder. Ther Adv Urol. 2021;13:17562872211018006.